Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Thursday, June 27, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences announced a presentation at the UMDF Mitochondrial Medicine 2024 conference. The presentation will support the advancement of their PBGENE-PMM program towards an Investigational New Drug (IND) application and/or Clinical Trial Application (CTA) in 2025. This marks a significant step in their gene editing therapy development.
Price reaction · baseline $9.67 (2024-06-26 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation at a significant conference highlights progress.
  • Advancement towards IND and/or CTA indicates strong development pipeline.
  • Use of proprietary ARCUS platform showcases innovative technology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Jun. 27, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

Frequently Asked Questions

What is the PBGENE-PMM program?

The PBGENE-PMM program focuses on developing gene editing therapies using Precision BioSciences' ARCUS platform.

When is the UMDF Mitochondrial Medicine 2024 conference?

The UMDF Mitochondrial Medicine 2024 conference is scheduled for June 2024.

What is the significance of the IND application?

The IND application is crucial for initiating clinical trials for new therapies.

What technology does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences PBGENE-PMM gene editing ARCUS platform IND application
Last updated: Jun 27, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →